Tristel Solutions Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tristel Solutions Ltd. - overview
Established
1993
Location
-, Cambridgeshire, UK
Primary Industry
Chemicals
About
Tristel Solutions Ltd. develops advanced disinfection solutions utilizing chlorine dioxide to ensure safe hygiene in healthcare environments. Their portfolio addresses critical needs in medical device and surface decontamination, effectively combating harmful pathogens. Founded in 1993 and headquartered in the UK, Tristel Solutions Ltd.
specializes in high-level disinfection solutions. The company operates globally, with a focus on markets including the United Kingdom, Europe, Asia, and North America. Juraj Maly and Paul Swinney currently lead the company as CEOs, bringing significant experience in healthcare innovation. Tristel specializes in high-level disinfection solutions utilizing the biocidal properties of chlorine dioxide.
The company’s product portfolio is centered around the decontamination of medical devices and surfaces, ensuring efficacy against harmful pathogens, including bacterial spores. Their flagship offerings include the Tristel Trio Wipes System, Tristel DUO ULT, and Tristel DUO OPH, designed for various healthcare settings such as hospitals, care homes, and dental practices. Additionally, Tristel provides a digital traceability platform that integrates with its decontamination products, enhancing visibility into each decontamination event. The company’s solutions cater to clients across several geographical markets, including the United Kingdom, Europe, Asia, and North America, serving a diverse client base from healthcare providers to institutional facilities.
In the most recent year, Tristel reported revenue of USD 52. 81 mn, with an EBITDA of USD 12. 20 mn. The company generates revenue primarily through the sale of its disinfection products and digital compliance tools, operating on a B2B model.
Customers place orders directly with the company or through authorized distributors, fostering long-term partnerships with healthcare institutions. The revenue structure includes direct sales of individual products, such as the Tristel DUO series and Trio Wipes, as well as potential service agreements for ongoing support and product integration. Pricing plans are structured to reflect the comprehensive nature of the solutions offered, considering aspects such as volume and frequency of purchases. The company’s commitment to providing reliable and effective disinfection solutions ensures a steady demand from its existing client base while also attracting new customers in the healthcare sector.
Primary Industry
Chemicals
Sub Industries
Chemicals
Website
www.tristel.com
Total Amount Raised
Subscriber access only
Tristel Solutions Ltd. - financials
| Fiscal Year Ended | Jun 30, 2010 | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 7,979,593 | 9,266,303 | 10,452,020 | 10,003,715 | 12,684,826 | 14,688,334 | 14,913,205 | 15,214,337 | 15,693,000 | 17,833,000 | 20,974,000 | 18,909,000 | 17,586,000 | - | - | - |
| % Revenue Growth (YoY) | - | 16.1% | 12.8% | (4.3%) | 26.8% | 15.8% | 1.5% | 2.0% | 3.1% | 13.6% | 17.6% | (9.8%) | (7.0%) | - | - | - |
| EBITDA (USD) | 1,055,900 | 795,700 | 1,022,604 | (1,118,096) | 1,270,552 | 2,126,543 | 3,356,948 | 3,668,318 | 3,766,000 | 4,314,000 | 5,836,000 | 5,447,000 | 5,326,000 | - | - | - |
| Operating Income (USD) | 666,644 | 252,159 | 92,630 | (2,013,037) | 517,474 | 1,427,163 | 2,644,197 | 2,872,352 | 3,003,000 | 3,583,000 | 4,564,000 | 4,127,000 | 3,942,000 | - | - | - |
| Operating Margin | 8.4% | 2.7% | 0.9% | (20.1%) | 4.1% | 9.7% | 17.7% | 18.9% | 19.1% | 20.1% | 21.8% | 21.8% | 22.4% | - | - | - |
| % EBITDA Margin | 13.2% | 8.6% | 9.8% | (11.2%) | 10.0% | 14.5% | 22.5% | 24.1% | 24.0% | 24.2% | 27.8% | 28.8% | 30.3% | - | - | - |
| NET Income (USD) | 480,896 | 98,800 | 157,410 | (1,509,454) | 165,920 | 1,322,265 | 2,263,652 | 2,947,412 | 3,108,000 | 3,593,000 | 4,036,000 | 4,334,000 | 2,680,000 | - | - | - |
| % Net Margin | 6.0% | 1.1% | 1.5% | (15.1%) | 1.3% | 9.0% | 15.2% | 19.4% | 19.8% | 20.1% | 19.2% | 22.9% | 15.2% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.